Health, Spirituality and Medical Ethics - Vol.4, No.1, Mar 2017 The Effect of Agnugol Tablet on Oligomenorrhea in Patients with Polycystic Ovary Syndrome: A Clinical Trial Received 14 Jun 2016; Accepted 12 Jul 2016 Arezoo Shayan 1 , Fatemeh Shobeiri 2 , Arash Khalili 1 , Sayedeh Zahra Masoumi 2* 1 School of Nursing and Midwifery, Hamadan University of Medical Sciences, Hamadan, Iran. 2 Mother and Child Care Research Center, Hamadan University of Medical Sciences, Hamadan, Iran. * Correspondence: Should be addressed to Ms. Sayedeh Zahra Masoumi. Email: Masoumi@yahoo.com Introduction olycystic ovary syndrome (PCOS) is a relatively common disorder among women of reproductive age. The clinical manifestations of PCOS include oligomenorrhea, amenorrhea, hirsutism, acne, and infertility (1). This syndrome is a type of hormonal imbalance in women of reproductive age that affects one in 16 women (2). The main cause of PCOS has not yet been determined but hyperinsulinemia and insulin resistance seem to play important roles in development of PCOS. The main symptoms of PCOS include hyperandrogenism and chronic anovulation. This disease presents with morphological manifestations of polycystic ovary observed in ultrasound examination, obesity, hyperandrogenism, menstrual disorders, and infertility that may be seen separately or in combination(3). Metabolic disorders including increased levels of LH, testosterone, insulin, and prolactin are common among PCOS patients (4). Recently, 66% of people with PCOS have been found to suffer from anovulation which is mainly associated with oligomenorrhea and secondary amenorrhea and is characterized with clinical or laboratory evidence of hyperandrogenemia (5- 7). Hormonal disorders are the most important cause of oligomenorrhea, including anovulation and the diseases associated with hyperandrogenemia such as PCOS, adrenal hyperplasia, hyperprolactinemia, and thyroid disorders (8,9). When menstrual cycles occur more than 35 days apart, oligomenorrhea is P Abstract Background and Objectives: Polycystic ovary syndrome (PCOS) is a relatively common disorder among women of reproductive age. The clinical manifestations of PCOS include oligomenorrhea, amenorrhea, hirsutism, acne, and infertility. This study was conducted to evaluate the effect of Agnugol on oligomenorrhea in patients with PCOS. Methods: This clinical trial was conducted on 60 women with PCOS and oligomenorrhea referred to the Gynecological Diseases Clinic of Fatemiyeh Hospital, Hamedan in 2015-2016. The participants were treated with Agnugol for three months and filled out a researcher-developed questionnaire before and at the end of each month of the intervention. The data were analyzed by descriptive statistics, Wilcoxon test, and Friedman test in SPSS 21. Results: The mean (standard deviation) age of the participants was 39.45 (4.60) years. According to Wilcoxon and Friedman tests, no significant differences were seen in bleeding duration, menstrual cycles, and the number of used pads between before and after (at the end of each month of) the intervention (P<0.001). Bleeding periods decreased from 40.96 days before the intervention to 25.83 days at the end of the third month. Moreover, the number of used pads increased from four before the intervention to 12 at the end of the third month and the bleeding period from four days before the intervention to six days at the end of the third month (P<0.001). Conclusion: Many people with PCOS suffer from oligomenorrhea. Agnugol is effective in treating oligomenorrhea in people with PCOS, and regulating menstrual cycle. Because Agnugol is a plant-based drug and has few side effects, it can be used as an effective drug for these disorders. Keywords: Agnugol, Oligomenorrhea, Polycystic Ovary Syndrome. Original Article Health, Spirituality and Medical Ethics. 2017;4(1):22-27 Please Cite This Article As: Shayan A, Shobeiri F, Khalili A, Masoumi SZ. The effect of Agnugol tablet on oligo- menorrhea in patients with polycystic ovary syndrome: A clinical trial. Health Spiritual Med Ethics. 2017;4(1):22-7.